Nevoid basal cell carcinoma syndrome (NBCCS, or Gorlin\'s syndrome) is an autosomal dominant syndrome predisposing to basal cell carcinomas (BCCs) and numerous developmental abnormalities ([Gorlin, 2004](#bib13){ref-type="other"}). The prevalence is estimated at one per 57 000 ([Evans *et al*, 1991](#bib7){ref-type="other"}); approximately 0.4% of all cases of BCC and 2% of BCC patients under 45 years of age are affected by NBCCS ([Farndon *et al*, 1992](#bib8){ref-type="other"}).

NBCCS has been linked to germline mutations in the human homologue of the *Drosophila* segment polarity gene patched (*PTCH*) ([Hahn *et al*, 1996](#bib14){ref-type="other"}; [Johnson *et al*, 1996](#bib16){ref-type="other"}), and the rate of neomutation is high ([Shanley *et al*, 1994](#bib25){ref-type="other"}). The *PTCH* mutation frequency in NBCCS patients reported varies considerably in the different studies, ranging from 40 to 80% ([Kimonis *et al*, 2004](#bib17){ref-type="other"}; [Marsh *et al*, 2005](#bib19){ref-type="other"}).

The *PTCH* gene consists of 23 exons, and encodes a 1447-amino-acid integral membrane protein, with 12 transmembrane regions, two extracellular loops, and a putative sterol-sensing domain. Most *PTCH* germline mutations are predicted to lead to premature truncation of the Ptc1 protein, and assumed to represent null *PTCH* alleles ([Wicking and Bale, 1997](#bib29){ref-type="other"}), suggesting that many aspects of the phenotype apart from BCC result from haploinsufficiency. Tumours in NBCCS patients are likely to arise when the remaining *PTCH* allele is inactivated, which would be consistent with *PTCH* acting as a tumour suppressor gene ([Gailani *et al*, 1992](#bib10){ref-type="other"}).

In addition, deletions of interstitial chromosome 9q have been identified in some NBCCS patients ([Olivieri *et al*, 2003](#bib22){ref-type="other"}; [Haniffa *et al*, 2004](#bib15){ref-type="other"}; [Boonen *et al*, 2005](#bib3){ref-type="other"}).

One problem that arises is the possibility of a misdiagnosis of NBCCS, because of the complex phenotype of this syndrome. Various clinical and radiological criteria have been used to diagnose NBCCS; these are categorised as major and minor criteria. Nevoid basal cell carcinoma syndrome is considered to be certain when at least two of the four major criteria are present (multiple BCC (MBCCs), palmar and plantar epidermal pits, jaw keratocysts, and cerebral calcification) ([Shanley *et al*, 1994](#bib25){ref-type="other"}). Patients may also display many other clinical features that are classified as minor criteria ([Table 1](#tbl1){ref-type="table"}) ([Lo Muzio *et al*, 1999](#bib18){ref-type="other"}).

In addition to NBCCS, recent publications suggest that allelic variation of *PTCH* could also influence susceptibility to BCC ([Strange *et al*, 2004a](#bib27){ref-type="other"}, [2004b](#bib28){ref-type="other"}; [Asplund *et al*, 2005](#bib2){ref-type="other"}). In particular, some *PTCH* haplotypes, including polymorphisms in exon 23 (c.3944C), intron 15 (G^2560+9^), or exon 12 (c.1686C), seem to have a potentially protective effect against BCC ([Strange *et al*, 2004a](#bib27){ref-type="other"}, [2004b](#bib28){ref-type="other"}).

The goal of this study was to search for *PTCH* germline abnormalities both in patients harbouring all the criteria for NBCCS and in those clinically suspected of having a genetic predisposition towards BCC (MBCC and/or BCC while under 40 years of age and/or familial BCC).

PATIENTS AND METHODS
====================

Selection of patients
---------------------

This study was performed from 2003 to January 2005. Patients were enrolled at the Saint Louis (60%), Ambroise Paré (25%), Bichat-Claude Bernard (5%), Tarnier (5%), and Henri Mondor (5%) hospitals, all of which are located in or near the city of Paris (France). Sixty-five patients were prospectively enrolled in the study, 10% of whom were newly diagnosed cases. Two different categories of patients were studied: Patients affected by the typical NBCCS (17 index cases: three familial and 14 sporadic) who displayed at least two of the major criteria (MBCC, palmo-plantar pits, cerebral calcifications, odontogenic keratocysts) or one major criterion plus at least two minor criteria as defined by [Shanley *et al* (1994](#bib25){ref-type="other"}). In addition, seven additional NBCCS patients from the three enrolled families were also studied.Patients strongly suspected of having a genetic predisposition towards BCC (48 cases), characterised by either (i) MBCCs (35 cases), defined as the presence of at least two BCCs in the same patient confirmed by pathology reports, and/or (ii) BCC in patients under 40 years of age (28 cases) and/or (iii) familial BCC (10 cases), defined as the presence of at least two BCC cases in first- or second-degree relatives (all cases confirmed by pathology reports). For familial BCC cases, only the proband was enrolled. To exclude the presence of NBCCS features in this 'BCC-predisposed\' non-NBCCS group, a careful clinical exam was realised to search for BCC, pits on palm and soles, facial, ocular, and limbs abnormalities. In addition, dental and crane X-rays were also performed in order to verify the absence of odontogenic keratocysts and intracranial calcifications.

Written informed consent, agreeing to peripheral blood sampling and genetic analysis, was obtained from each patient enrolled in the study. Genomic DNA was isolated from peripheral blood leucocytes of all the participants by routine methods ([Miller *et al*, 1988](#bib21){ref-type="other"}).

*PTCH* sequencing
-----------------

The 23 exons of the *PTCH* coding sequence were amplified using 23 primer pairs ([Table 2](#tbl2){ref-type="table"}). PCR conditions included 35 denaturing cycles at 95°C for 30 s, annealing at 60°C for 30 s, elongation at 72°C for 45 s for exons 1 and 4; and 35 denaturing cycles at 96°C for 30 s, annealing at 63°C for 30 s, elongation at 72°C for 1 min for exons 5--23. Sequence analysis was performed on an ABI-Prism 3100 automated DNA sequencer using 10 ng PCR purified products and Big-Dye Terminator Cycle Sequencing kits (Perkin Elmer, Courtaboeuf cedex, France), according to the manufacturer\'s instructions. The functionality of the nonsynonymous variant was predicted using the *Polyphen* and SIFT informatics program (<http://tux.EMBL-Heidelberg.DE/ramensky/>; <http://blocks.fhcrc.org/sift/SIFT_seq_submit2.html>).

*PTCH* deletion analysis
------------------------

### Real-time quantitative PCR

Real-time quantitative PCR was performed using SYBR Green I dye as a fluorescent signal. This dye binds specifically to the minor groove of double-stranded DNA, making it possible to detect PCR product formation ([Ginzinger, 2002](#bib12){ref-type="other"}).

In order to examine both ends of *PTCH*, two targets were initially chosen on *PTCH* exons 1 and 23, and then, to extend the analysis, two other *PTCH* targets on exons 4 and 15, respectively, were also examined ([Table 2](#tbl2){ref-type="table"}). Two single-copy sequences were used as reference sequences: MYH9, mapping at 22q13.1, and Rb, mapping at 13q. Five microlitres of DNA was added to the PCR reaction mixture containing 1 × SYBR Green buffer (Applied Biosystems, Courtaboeuf cedex, France), 300 n[M]{.smallcaps} forward and reverse primers, 5 m[M]{.smallcaps} MgCl~2~ (3 m[M]{.smallcaps} for 8q11 SST), 200 *μ*[M]{.smallcaps} dNTP, and 0.6 U of AmpliTaq Gold (Applied Biosystems) in a final volume of 25 *μ*l.

Each series of PCR reactions included two negative controls, containing water in place of DNA, and a five-point standard curve. The standard curve was plotted using serial dilutions of normal PBMC in Tris (10 m[M]{.smallcaps})--EDTA (1 m[M]{.smallcaps}) buffer, ranging from 10 to 0.02 ng *μ*l^−1^ (corresponding to 50--0.1 ng of DNA analysed per well). The same dilutions were used for all targets and reference sequences. PCR was performed on the ABI PRISM 7700 Sequence detector system (Applied Biosystems). All analyses were performed in duplicate. The PCR amplification profile was as follows: initial denaturing at 95°C for 10 min, followed by 40 denaturing cycles at 95°C for 10 s, and a combined annealing and extension step at 65°C for 1 min. Detection of the fluorescent product was carried out at the end of the extension period. To confirm amplification specificity, the PCR products from each primer pair were subjected to a melting curve analysis, and subsequent agarose gel electrophoresis. The concentration of each gene was calculated based on the appropriate calibration curve. Relative copy numbers of *PTCH* were then obtained by calculating the ratio of the result obtained for each target to the MYH9 and Rb value. The normalised ratio of each target on MYH9 and Rb was expected to be close to 1, if no deletion had occurred.

Microsatellite analysis
-----------------------

Two microsatellite markers were studied: (i) a CGG repeat localised in the 5′UTR, which was genotyped by sequencing *PTCH* exon 1, and (ii) a CA repeat localised in intron 2 ([Aboulkassim *et al*, 2003](#bib1){ref-type="other"}), which was genotyped by migration of the fluorescent-labelled PCR product on a 310 Genetic Analyzer (Applied Biosystems).

Multiplex ligation-dependent probe amplification
------------------------------------------------

*PTCH* deletion was also investigated by multiplex ligation-dependent probe amplification (MLPA), a quantitative, multiplex PCR method, as described previously ([Gille *et al*, 2002](#bib11){ref-type="other"}). Multiplex ligation-dependent probe amplification was used to determine the relative copy number of each of the 23 *PTCH* exons, and was performed using an available commercial kit (SALSA MLPA KIT P067 PTCH, mrc-Holland).

RESULTS
=======

Seventeen patients were considered to have NBCCS, on the basis of the presence of two major criteria, or of one major criterion plus two or more minor criteria. Three were nonrelated familial cases, and 14 were sporadic cases. The three families had, respectively, four, three, and two NBCCS patients, all first-degree related. Thirteen patients had two or more major NBCCS criteria (four patients with two major criteria, seven patients with three major criteria, and two patients with all four criteria). Four NBCCS patients had only one major criterion plus two, four or five minor criteria. The frequencies of the major criteria were as follows: MBCC (88%), palmo-plantar pits (78%), odontogenic keratocysts (70%), and cerebral calcifications (57%). The most frequent 'minor\' criteria were macrocephaly (70%), epidermal cysts (60%), scoliosis (60%), hypertelorism (50%), and strabism (36%). The median age at the first BCC in this NBCCS group was 27 years.

Forty-eight patients suspected of being predisposed to BCC were characterised by either (i) the occurrence of MBCC (35 cases) and/or (ii) the occurrence of BCC before the age of 40 years (28 cases), and/or (iii) the presence of familial BCC (10 cases), defined as the presence of at least two BCC cases in first- or second-degree relatives. The median age at the first BCC in this group was 42 years.

*PTCH* mutations were identified in 12 out of 17 patients harbouring the full complement of criteria for NBCCS. These were frameshift mutations in five patients, nonsense mutations in five patients, and one in frame deletion in one patient (see [Table 3](#tbl3){ref-type="table"}). An identical, nonsense mutation, W129X, was characterised in two unrelated patients. *PTCH* mutations were detected in all three familial cases, and were shown to segregate with the disease in the families, as they were detected in all the seven relatives affected by NBCCS ([Table 3](#tbl3){ref-type="table"}).

In addition, a large germline deletion was detected in another typical NBCCS patient. Quantitative PCR analysis showed that three of the four exons examined (4, 15, 23) were deleted, whereas the first exon was not. As the patient was heterozygous for a microsatellite localised in intron 2, this means that the deletion must begin after exon 2 of *PTCH*. These results were confirmed by MLPA, with a 50% reduction in signal intensity from exons 5 to 23, whereas exon 3 was normal. As the MLPA kit does not explore exon 4, both results are concordant and show the presence of a large *PTCH* deletion including exons 4--23. *PTCH* deletions were also looked for in the five remaining NBCCS patients who did not harbour any *PTCH* mutation, but none was found. To summarise, therefore, germline mutations or deletions of *PTCH* were present in 70% of NBCCS patients.

In contrast, in the BCC group without any other criterion for NBCCS, only one missense variant, G774R, was found in a patient affected with MBCC. This patient had five different BCCs, all localised in the head and neck region, the first BCC being diagnosed at the age of 46 years. This variant localised in the putative fourth extracellular domain, and is predicted to be damaging by the SNP prediction programs Polyphen and SIFT (<http://tux.embl-heidelberg.de/ramensky/>; <http://blocks.fhcrc.org/sift/SIFT.html>). No large deletions of *PTCH* were observed by real-time PCR or MLPA in the remaining patients with a suspected genetic predisposition to BCC.

DISCUSSION
==========

In this study, we identified *PTCH* mutations or deletions in 12 out of 17 patients with NBCCS (70%). As far as we know, only one study has been performed in the French population ([Boutet *et al*, 2003](#bib4){ref-type="other"}). Of the 11 mutations identified in NBCCS patients, 10 resulted in truncation of the *PTCH* protein owing to frameshifts or nonsense mutations. This is consistent with the finding that most (86%) mutations lead to premature termination of the protein ([Wicking *et al*, 1997](#bib30){ref-type="other"}; [Fujii *et al*, 2003](#bib9){ref-type="other"}).

Previously, *PTCH* mutations have been found in 40--80% of NBCCS patients ([Chidambaram *et al*, 1996](#bib5){ref-type="other"}; [Wicking *et al*, 1997](#bib30){ref-type="other"}; [Boutet *et al*, 2003](#bib4){ref-type="other"}). Although our group is quite small, the exhaustive screening for *PTCH* exons and flanking intronic regions by direct sequencing and deletion analysis may have increased the mutation detection rate.

We identified a large *PTCH* deletion in a patient harbouring the typical signs of NBCCS. In all, five patients that share NBCCS features were previously been reported to carry an interstitial chromosome 9q deletion identified by cytogenetic analysis ([Shimkets *et al*, 1996](#bib26){ref-type="other"}; [Sasaki *et al*, 2000](#bib24){ref-type="other"}; [Haniffa *et al*, 2004](#bib15){ref-type="other"}; [Midro *et al*, 2004](#bib20){ref-type="other"}). This indicates that large *PTCH* deletions are not a rare mechanism of *PTCH* inactivation, and this possibility should be investigated if no *PTCH* mutation is detected.

Despite the exhaustive analysis, no *PTCH* mutation or large deletion was found in five of the NBCCS patients. This is likely to be due to the existence of mutations outside the regions analysed possibly in introns or regulatory elements. An alternative hypothesis could be the presence of a somatic mosaicism, or the existence of mutations in another gene implicated in the sonic hedgehog pathway, as has been shown to occur in sporadic BCC ([Reifenberger *et al*, 1998](#bib23){ref-type="other"}; [Xie *et al*, 1998](#bib31){ref-type="other"}).

In the group of BCC patients without any other NBCCS criterion, only one missense mutation (G774R) was found in a patient with MBCC without any other NBCCS criteria (in particular, this patient had a normal head circumference, no facial or ocular abnormalities, and the chest and crane X-rays did not show any skeletal abnormality or intracranial calcification). Unfortunately, segregation could not be assessed because his parents were deceased. Therefore, the significance of this amino-acid substitution will not become completely clear until a functional analysis is performed. However, this could be a causative mutation, as (i) it is predicted to be damaging by two bioinformatic programs *Polyphen* and *SIFT* and (ii) it was not reported in any previous study or in the NCBI SNP database. On the other hand, we cannot exclude the possibility that this could be a rare polymorphism.

We did not found any other *PTCH* mutation in this group (*P*\<0.0001), which indicates that when other NBCCS criteria are absent, *PTCH* mutations are rarely involved in predisposition to BCC. Nevertheless, it remains possible that *PTCH* polymorphisms located outside the coding sequence or intron--exon junctions could influence BCC susceptibility, as has been suggested by recent publications ([Strange *et al*, 2004a](#bib27){ref-type="other"}, [2004b](#bib28){ref-type="other"}; [Asplund *et al*, 2005](#bib2){ref-type="other"}).

In conclusion, germline abnormalities (mutations and deletions) of *PTCH* are very predominantly observed in patients with the full criteria for NBCCS. We therefore suggest that patients harbouring the full complement of NBCCS criteria should, as a priority, be screened for *PTCH* mutations by sequencing, followed by a deletion analysis if no mutation is detected. The finding of a *PTCH* mutation confirms the clinical diagnosis of NBCCS, therefore validating the clinical and radiological diagnostic criteria of this syndrome. The molecular confirmation of NBCCS diagnosis permits a better clinical monitoring (in particular, dermatological), a choice of the rational therapeutic (e.g. avoiding radiotherapy for treatment of BCCs). Moreover, it makes it possible to carry out a genetic council in the families concerned, and to offer the possibility of antenatal diagnosis if the families wish it.

###### 

NBCCS minor criteria

  **NBCCS minor criteria**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Congenital skeletal anomaly: bifid, fused, splayed, or missing rib, bifid, wedged or fused vertebra, cyphoscoliosis, brachydactyly, short fourth metacarpal, short thumb terminal phalanx
  Macrocephaly, frontal bossing, prognathism
  Congenital mouth malformation: cleft lip or palate, coarse face, polydactyly
  Eye anomaly: strabismus, hyperthelorism, cataract, coloboma, microphtalmia
  Cardiac or ovarian fibroma
  Medulloblastoma
  Lymphomesenteric cysts, congenital lung cyst
  Mental retardation

NBCCS=nevoid basal cell carcinoma syndrome.

###### 

*PTCH* PCR primers

  **Exon number**             **Primer name**   **Primer sequence (5′ → 3′)**
  --------------------------- ----------------- ----------------------------------------
  *Sequencing primers*                          
   1                          PTCH Ex 01F       TGG AAG GCG CAG GGT CTG ACT
                              PTCH Ex 01 R      CGA TCC CAA AGA GTT AGA GGA
   2                          PTCH Ex 02F       CTG CGG CCC GGC TTT ATG AC
                              PTCH Ex 02R       GTG TGC GCT GGC GAA TAT CTC TAT C
   3                          PTCH Ex 03F       ACT GCT CAC ACA TCA GCC AGT CTC AT
                              PTCH Ex 03R       GCA TTT CCA GGG CAA CTT CAT TTA CTA
   4--5                       PTCH Ex 04--05F   GCT GGG TCT CTA CTT GGC AAA AGC
                              PTCH Ex 04--05R   CCC GAC TAT TCA CTC AAA AAA TGC ACA
   6                          PTCH Ex 06F       ATT TGT TTT GAT GCC AGA GTC CCA GA
                              PTCH Ex 06R       GGC TAA TGG GAG GTG TAT GGC AAA TC
   7                          PTCH Ex 07F       AAG ATT TGC CAT ACA CCT CCC ATT AGC
                              PTCH Ex 07R       AAT TCC CCA CAA GGT GCT TTT TCA A
   8                          PTCH Ex 08F       GGA AAC ATG TGC TCA CAG AGA AGG AAA
                              PTCH Ex 08R       TCC CAT CAA GTT CCC AGA ATT GCA
   9                          PTCH Ex 09F       CCC TGC CCT GGA ATC ACG TAG AAC
                              PTCH Ex 09R       GAA GCA GGA GCA GTC ATG GAA AAG TAA
   10                         PTCH Ex 10F       TTT GCC GTT TGC CTA CCT TTG ACT C
                              PTCH Ex 10R       CGG TGA GAA GGA CAC ACA GCA CAC
   11                         PTCH Ex 11F       AGG TGC TGG TGG CAG AGT CCT AAC TA
                              PTCH Ex 11R       GCA GCC AGT GAC ACA TCA TCT GAC AT
   12                         PTCH Ex 12F       CTG CCA CGT ATC TGC TCA CAC AGT C
                              PTCH Ex 12R       CAC CCA GTT AAA CAG AGC CTC AAA CAC
   13                         PTCH Ex 13F       CAC GGT TTC AAA TGC TTC AAG AGG A
                              PTCH Ex 13R       CAA ACC CCG TTA CCC ACA TTC CTT
   14                         PTCH Ex 14F       CAG GCG ATG AAC CAG GTG ATG TTA T
                              PTCH Ex 14R       GAA GCA ATC TGA TGA ACT CCA AAG GTT
   15                         PTCH Ex 15F       TTG TCC AGG AAG AGT CAG TGG TGC TC
                              PTCH Ex 15R       GTT GAA GCT GAA CAC GCA AAA GAC C
   16                         PTCH Ex 16F       CCC TGC CCT GCT CAG TCT CCT C
                              PTCH Ex 16R       CTG GCA TGA GGT CAC ACA ATT AGC TG
   17                         PTCH Ex 17F       GCC AGT GAT TGC ATC CTC CGA TAA
                              PTCH Ex 17R       CCA TTA CAC ATC CTC GTC TCC CAG AG
   18                         PTCH Ex 18F       CCT CAC AAA GAA TGA CTG CTG GAA GAT
                              PTCH Ex 18R       CCA GAG GCC CAG ACA TAA ACA AAA CTT
   19                         PTCH Ex 19F       AAG GTT CCC ACT TGG AGA CAA ACA GAG
                              PTCH Ex 19R       TGA ATT AGG CAG TAA AGG CAG TGT CCA
   20                         PTCH Ex 20F       TAC GTC AAC ACC AAA TAT GAC CCA GTG
                              PTCH Ex 20R       TCT GCC TCA GCC TCC CAA GTA GC
   21                         PTCH Ex 21F       TGA ATG TGA ACT GCG GTT GGA TAA CA
                              PTCH Ex 21R       CCA GTA CAC CGA AGA GGA AAA CAG ACA
   22                         PTCH Ex 22F       CCC CTG AAA AAT ACC GTG CTT TGA G
                              PTCH Ex 22R       ATC TGC CTG TGT GAT GTG CTG CTC
   23                         PTCH Ex 23F       GGG TTG ACT GAG TCT TTG GTG AAA CC
                              PTCH Ex 23R       TTG TCC TCC TCT TTG CCT GGC TCT A
                                                 
  *Quantitative PCR primer*                     
                              PTCHqex1F         CCA AAG AGT TAG AGG AGG GAA GAG AAA GT
                              PTCHqex1R         CTA TCT GCA CCG GCC CAG CTA C
                              PTCHqex4F         GCT GGG TCT CTA CTT GGC AAA AGC
                              PTCHqex4R         TTT CCA CTG CCT AAT AAA ATG AAA AGC
                              PTCHqex15F        AAG AAA ACA AAC AGC TTC CCA AAA TGT
                              PTCHqex15R        GTT GAA GCT GAA CAC GCA AAA GAC C
                              PTCHqex23F        TCC AGC CAG CCG TGT CAG AGA
                              PTCHqex23R        TTC CAC CCA CAA AAG AAA AGC CTG T

NBCCS=nevoid basal cell carcinoma syndrome; PTCH=patched.

###### 

*PTCH* mutations in NBCCS and MBCC patients

  **Patient**   **Diagnosis**    **Exon**  ***PTCH* mutation**    **Effect on protein**                                 **Familial**  **Segregation**
  ------------- --------------- ---------- ---------------------- ---------------------------------------------------- -------------- -----------------
  B249          NBCCS             4--23    del                    Truncated                                                  −        NA
  P270          NBCCS               2      c.385 G\>A             W129X                                                      −        NA
  B530          NBCCS               15     c.2443--2461 del 18    p\. I815N Del (Q816, H817, L818, L819, Y820, D821)         \+       Yes, four cases
  B344          NBCCS               15     c.2450 T\>A            L818X                                                      −        NA
  B370          NBCCS               17     c.2712 C\>T            Q905X                                                      −        ND
  B395          NBCCS               6      c.922 delG             p\. A308PfsX323                                            \+       Yes, two cases
  B401          NBCCS               18     c\. 2962 dup TT        p\. V988LfsX995                                            \+       Yes, one case
  B419          NBCCS               18     c.3053 G\>A            W1018X                                                     −        NA
  B420          NBCCS               17     c\. 2743 ins CATCATT   p\. N915Hins7fsX917                                        −        NA
  P433          NBCCS               2      c.260--265 delTTTA     p\. F88Ndel4fsX116                                         −        NA
  B484          NBCCS               2      c.291 insA             p\. N97KfsX139                                             −        NA
  B519          NBCCS               2      c.385 G\>A             W129X                                                      −        NA
  P345          MBCC                15     c.2320 G\>A            G774R                                                      −        NA

PCTH mutations are described using the nomenclature system for human gene mutations ([den Dunnen and Antonarakis, 2001](#bib6){ref-type="other"}).

MBCC=multiple basal cell carcinoma; NA=not applicable; NBCCS=nevoid basal cell carcinoma syndrome.
